Jeremy J Watts1, Maya R Jacobson1, Nittha Lalang1, Isabelle Boileau2, Rachel F Tyndale3, Michael Kiang4, Ruth A Ross5, Sylvain Houle6, Alan A Wilson6, Pablo Rusjan2, Romina Mizrahi7. 1. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. 2. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 3. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 4. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 5. Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. 6. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 7. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Electronic address: romina.mizrahi@camhpet.ca.
Abstract
BACKGROUND: The brain's endocannabinoid system, the primary target of cannabis, has been implicated in psychosis. The endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia. Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to positive psychotic symptoms. METHODS: Twenty-seven patients with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resolution positron emission tomography scans with the novel FAAH radioligand [11C]CURB and structural magnetic resonance imaging. Data were analyzed using the validated irreversible 2-tissue compartment model with a metabolite-corrected arterial input function. RESULTS: FAAH did not differ significantly between patients with psychotic disorders and healthy control subjects (F1,62.85 = 0.48, p = .49). In contrast, lower FAAH predicted greater positive psychotic symptom severity, with the strongest effect observed for the positive symptom dimension, which includes suspiciousness, delusions, unusual thought content, and hallucinations (F1,26.69 = 12.42, p = .002; Cohen's f = 0.42, large effect). Shorter duration of illness (F1,26.95 = 13.78, p = .001; Cohen's f = 0.39, medium to large effect) and duration of untreated psychosis predicted lower FAAH (F1,26.95 = 6.03, p = .021, Cohen's f = 0.27, medium effect). These results were not explained by past cannabis exposure or current intake of antipsychotic medications. FAAH exhibited marked differences across brain regions (F7,112.62 = 175.85, p < 1 × 10-56; Cohen's f > 1). Overall, FAAH was higher in female subjects than in male subjects (F1,62.84 = 10.05, p = .002; Cohen's f = 0.37). CONCLUSIONS: This first study of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of potential utility for clinical studies targeting psychotic symptoms or as a novel target for interventions to treat psychotic symptoms.
BACKGROUND: The brain's endocannabinoid system, the primary target of cannabis, has been implicated in psychosis. The endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia. Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to positive psychotic symptoms. METHODS: Twenty-seven patients with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resolution positron emission tomography scans with the novel FAAH radioligand [11C]CURB and structural magnetic resonance imaging. Data were analyzed using the validated irreversible 2-tissue compartment model with a metabolite-corrected arterial input function. RESULTS: FAAH did not differ significantly between patients with psychotic disorders and healthy control subjects (F1,62.85 = 0.48, p = .49). In contrast, lower FAAH predicted greater positive psychotic symptom severity, with the strongest effect observed for the positive symptom dimension, which includes suspiciousness, delusions, unusual thought content, and hallucinations (F1,26.69 = 12.42, p = .002; Cohen's f = 0.42, large effect). Shorter duration of illness (F1,26.95 = 13.78, p = .001; Cohen's f = 0.39, medium to large effect) and duration of untreated psychosis predicted lower FAAH (F1,26.95 = 6.03, p = .021, Cohen's f = 0.27, medium effect). These results were not explained by past cannabis exposure or current intake of antipsychotic medications. FAAH exhibited marked differences across brain regions (F7,112.62 = 175.85, p < 1 × 10-56; Cohen's f > 1). Overall, FAAH was higher in female subjects than in male subjects (F1,62.84 = 10.05, p = .002; Cohen's f = 0.37). CONCLUSIONS: This first study of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of potential utility for clinical studies targeting psychotic symptoms or as a novel target for interventions to treat psychotic symptoms.
Authors: Edwin J C G Van den Oord; Dan Rujescu; Jaime R Robles; Ina Giegling; Claire Birrell; József Bukszár; Lenn Murrelle; Hans-Jürgen Möller; Lefkos Middleton; Pierandrea Muglia Journal: Schizophr Res Date: 2005-10-17 Impact factor: 4.939
Authors: Dean F Wong; Hiroto Kuwabara; Andrew G Horti; Vanessa Raymont; James Brasic; Maria Guevara; Weiguo Ye; Robert F Dannals; Hayden T Ravert; Ayon Nandi; Arman Rahmim; Jeffrey E Ming; Igor Grachev; Christine Roy; Nicola Cascella Journal: Neuroimage Date: 2010-04-18 Impact factor: 6.556
Authors: Isabelle Boileau; Pablo M Rusjan; Belinda Williams; Esmaeil Mansouri; Romina Mizrahi; Vincenzo De Luca; Douglas S Johnson; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong Journal: J Cereb Blood Flow Metab Date: 2015-06-17 Impact factor: 6.200
Authors: F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli Journal: Schizophr Res Date: 2007-06-13 Impact factor: 4.939
Authors: Michael T Compton; Mary E Kelley; Claire E Ramsay; Makenya Pringle; Sandra M Goulding; Michelle L Esterberg; Tarianna Stewart; Elaine F Walker Journal: Am J Psychiatry Date: 2009-10-01 Impact factor: 18.112
Authors: Iva Dincheva; Andrew T Drysdale; Catherine A Hartley; David C Johnson; Deqiang Jing; Elizabeth C King; Stephen Ra; J Megan Gray; Ruirong Yang; Ann Marie DeGruccio; Chienchun Huang; Benjamin F Cravatt; Charles E Glatt; Matthew N Hill; B J Casey; Francis S Lee Journal: Nat Commun Date: 2015-03-03 Impact factor: 14.919
Authors: Nicola De Marchi; Luciano De Petrocellis; Pierangelo Orlando; Fabiana Daniele; Filomena Fezza; Vincenzo Di Marzo Journal: Lipids Health Dis Date: 2003-08-19 Impact factor: 3.876
Authors: Giulia Cisbani; Alex Koppel; Adam H Metherel; Mackenzie E Smith; Kankana N Aji; Ana C Andreazza; Romina Mizrahi; Richard P Bazinet Journal: Lipids Date: 2022-01-24 Impact factor: 1.880
Authors: Jeremy J Watts; Elisa Guma; Sofia Chavez; Rachel F Tyndale; Ruth A Ross; Sylvain Houle; Alan A Wilson; Mallar Chakravarty; Pablo M Rusjan; Romina Mizrahi Journal: Neuropsychopharmacology Date: 2022-07-29 Impact factor: 8.294
Authors: Lu Hou; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Cassis Varlow; Michael A Schafroth; Linjing Mu; Jiefeng Gan; Hao Xu; Christopher J Fowler; Ming-Rong Zhang; Neil Vasdev; Simon Ametamey; Benjamin F Cravatt; Lu Wang; Steven H Liang Journal: J Med Chem Date: 2020-12-30 Impact factor: 7.446